Minjung Seo1, Minyoung Oh1, Minjung Cho1, Sun Ju Chung2, Chong Sik Lee2, Jae Seung Kim1. 1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736 South Korea. 2. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Abstract
PURPOSE: (18)F-FP-CIT [(18)F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane] is useful for detecting striatal dopamine transporter (DAT). Since FP-CIT shows relatively high affinities for DAT and serotonin transporter (SERT), its binding can be influenced by selective serotonin reuptake inhibitors (SSRIs). We aimed to evaluate the effect of SSRIs on the binding of (18)F-FP-CIT. METHODS: In our (18)F-FP-CIT positron emission tomography (PET) data pool, images of 24 drug-naive Parkinson's disease (PD) patients (62.6 ± 10.6 years), 111 PD patients taking SSRIs [escitalopram (n = 19) and fluvoxamine (n = 20)] or clonazepam (n = 72), and 10 normal people were reviewed. PET images acquired 3 h after (18)F-FP-CIT injection were analyzed by an automated method using a predefined volume of interest (VOI) set of the striatum (ST), occipital cortex (OC), raphe nuclei (RN), and cerebellar cortex (CB). The uptake ratios (URs) of each VOI to the CB were compared among the groups. RESULTS: The ST/CB URs of all PD groups were significantly lower than that of normal group. When adjusted for drug severity, ST/CB URs were higher in drug-naive group but had no difference among antidepressant groups. Whereas OC/CB URs were not different among groups (p > 0.05), RN/CB URs were significantly lower in SSRI groups than in non-SSRI groups (p < 0.001) and showed similar results when adjusted for disease severity. CONCLUSIONS: PD patients taking SSRIs showed significantly decreased URs in the RN but not the OC. When adjusted for Hoehn and Yar (HY) score, ST URs were not different among antidepressant groups. This result suggests that the OC may be used as a reference region for the quantification of DAT binding in (18)F-FP-CIT PET images of PD patients taking SSRIs.
PURPOSE: (18)F-FP-CIT [(18)F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane] is useful for detecting striatal dopamine transporter (DAT). Since FP-CIT shows relatively high affinities for DAT and serotonin transporter (SERT), its binding can be influenced by selective serotonin reuptake inhibitors (SSRIs). We aimed to evaluate the effect of SSRIs on the binding of (18)F-FP-CIT. METHODS: In our (18)F-FP-CIT positron emission tomography (PET) data pool, images of 24 drug-naive Parkinson's disease (PD) patients (62.6 ± 10.6 years), 111 PDpatients taking SSRIs [escitalopram (n = 19) and fluvoxamine (n = 20)] or clonazepam (n = 72), and 10 normal people were reviewed. PET images acquired 3 h after (18)F-FP-CIT injection were analyzed by an automated method using a predefined volume of interest (VOI) set of the striatum (ST), occipital cortex (OC), raphe nuclei (RN), and cerebellar cortex (CB). The uptake ratios (URs) of each VOI to the CB were compared among the groups. RESULTS: The ST/CB URs of all PD groups were significantly lower than that of normal group. When adjusted for drug severity, ST/CB URs were higher in drug-naive group but had no difference among antidepressant groups. Whereas OC/CB URs were not different among groups (p > 0.05), RN/CB URs were significantly lower in SSRI groups than in non-SSRI groups (p < 0.001) and showed similar results when adjusted for disease severity. CONCLUSIONS:PDpatients taking SSRIs showed significantly decreased URs in the RN but not the OC. When adjusted for Hoehn and Yar (HY) score, ST URs were not different among antidepressant groups. This result suggests that the OC may be used as a reference region for the quantification of DAT binding in (18)F-FP-CIT PET images of PDpatients taking SSRIs.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: J Booij; G Andringa; L J Rijks; R J Vermeulen; K De Bruin; G J Boer; A G Janssen; E A Van Royen Journal: Synapse Date: 1997-11 Impact factor: 2.562
Authors: Maartje M L de Win; Jan B A Habraken; Liesbeth Reneman; Wim van den Brink; Gerard J den Heeten; Jan Booij Journal: Neuropsychopharmacology Date: 2005-05 Impact factor: 7.853
Authors: U Scheffel; J R Lever; P Abraham; K R Parham; W B Mathews; T Kopajtic; F I Carroll; M J Kuhar Journal: Synapse Date: 1997-04 Impact factor: 2.562
Authors: Minyoung Oh; Jae Seung Kim; Ji Young Kim; Kwang-Ho Shin; Seol Hoon Park; Hye Ok Kim; Dae Hyuk Moon; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee Journal: J Nucl Med Date: 2012-02-09 Impact factor: 10.057
Authors: Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne R Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Peter V Rabins; Howard D Weiss; Laura Marsh Journal: Am J Geriatr Psychiatry Date: 2013-03-29 Impact factor: 4.105
Authors: Christopher T Smith; M Danica San Juan; Linh C Dang; Daniel T Katz; Scott F Perkins; Leah L Burgess; Ronald L Cowan; H Charles Manning; Michael L Nickels; Daniel O Claassen; Gregory R Samanez-Larkin; David H Zald Journal: Transl Psychiatry Date: 2018-12-07 Impact factor: 6.222